Marvel Biosciences Extends TSXV Private Placement Deadline to Sept 14

Marvel Biosciences Corp., a Calgary-based biotechnology company specializing in pre-clinical drug redevelopment, has received approval from the TSX Venture Exchange (TSXV) to extend its private placement filing deadline. The company originally announced plans to file final closing materials with TSXV on August 31, 2026, but the deadline has now been moved to September 14, 2026. This extension follows an initial private placement announcement on July 16, 2026, and a subsequent update on August 19, 2026, outlining the firm’s plans to raise capital through synthetic chemical derivatives of off-patent drugs targeting adenosine receptor inhibition. The company’s approach focuses on developing new indications for approved pharmaceuticals, with key targets including neurological conditions such as depression, anxiety, Alzheimer’s disease, and ADHD, as well as non-neurological applications like cancer and non-alcoholic steatohepatitis. Marvel Biotechnology Inc., the company’s wholly owned subsidiary, continues to operate in Calgary, Alberta, under the TSXV listing for its private placement efforts.